Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies

Adjuvant Docetaxel for Node-Positive Breast Cancer

Miguel Martín, Tadeusz Pieńkowski, John R. Mackey et al. · New England Journal of Medicine · 2005 · 952 citations · Full text

Medicine, Oncology, Pharmacology +13

Doxorubicin cardiotoxicity: analysis of prevailing hypotheses

Richard D. Olson, Phillip S. Mushlin · The FASEB Journal · 1990 · 687 citations

Medicine, Pharmacology, Toxicology +16

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

Luca Gianni, Elisabetta Munzone, Giuseppe Capri et al. · Journal of Clinical Oncology · 1995 · 559 citations

Medicine, Oncology, Pharmacology +17

Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial

Jean‐Marc Nabholtz, Carla I. Falkson, J. Szántó et al. · Journal of Clinical Oncology · 2003 · 384 citations

Medicine, Oncology, Pharmacology +12

Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.

Richard D. Olson, Phillip S. Mushlin, Dean E. Brenner et al. · Proceedings of the National Academy of Sciences · 1988 · 354 citations · Full text

Medicine, Cardiology, Pharmacology +15